Extract Interstitial lung disease (ILD) associated with anti-melanoma differentiation-associated protein 5 antibody-positive (anti-MDA5 + ) dermatomyositis (DM) has a 6-month mortality rate of 33 - 66% despite aggressive immunosuppression, with rapidly progressive (RP)-ILD as the primary driver [1 - 4]. While elevated serum ferritin (SF) is an established prognostic biomarker in anti-MDA5 + DM, particularly among patients with RP-ILD, previous studies have relied on single time-point measurements with inconsistent cut-offs due to heterogeneity [5 - 7], and comprehensive characterisation of dynamic SF patterns during treatment in the real world is lacking.
European Respiratory Journal published a clinical update in Critical Care on 02 Apr 2026. The item focuses on Serum ferritin trajectories predict mortality risk in anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis: a longitudinal cohort study. Open the detail page to review the full original feed content.